Interleukin-2 therapy for advanced chronic myeloid leukemia

Mark Goodman, N. Spector, G. Rodrigues, P. A. Cassileth

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Chronic myeloid leukemia (CML) is usually treated with either alpha-interferon or hydrea. Median survival is 6 years. Eventually, in most CML patients, the disease evolves to blast phase with clinical and morphologic characteristics of an acute leukemia. This phase is commonly associated with systemic symptoms and the appearance of new cytogenetic abnormalities. Therapy for this phase is of limited value, resulting in a mean survival of 4 months. We describe four consecutive patients seen at our clinic with advanced stage CML (three blast, one accelerated phase) who were treated with interleukin-2 (Proleukin). The mean survival in these patients was 22 months (range 9-35 months) and two are still alive 25 and 35 months after the start of therapy. One patient had a complete cytogenetic response and another a partial response. Toxicity was minimal and no patient had to discontinue therapy because of it.

Original languageEnglish
Pages (from-to)1682-1684
Number of pages3
JournalLeukemia
Volume12
Issue number11
StatePublished - Nov 16 1998

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interleukin-2
Survival
Blast Crisis
Therapeutics
Hydroxyurea
Interferon-alpha
Cytogenetics
Chromosome Aberrations
Leukemia

Keywords

  • Blast crisis
  • Chronic myeloid leukemia
  • Interleukin-2 therapy

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Goodman, M., Spector, N., Rodrigues, G., & Cassileth, P. A. (1998). Interleukin-2 therapy for advanced chronic myeloid leukemia. Leukemia, 12(11), 1682-1684.

Interleukin-2 therapy for advanced chronic myeloid leukemia. / Goodman, Mark; Spector, N.; Rodrigues, G.; Cassileth, P. A.

In: Leukemia, Vol. 12, No. 11, 16.11.1998, p. 1682-1684.

Research output: Contribution to journalArticle

Goodman, M, Spector, N, Rodrigues, G & Cassileth, PA 1998, 'Interleukin-2 therapy for advanced chronic myeloid leukemia', Leukemia, vol. 12, no. 11, pp. 1682-1684.
Goodman M, Spector N, Rodrigues G, Cassileth PA. Interleukin-2 therapy for advanced chronic myeloid leukemia. Leukemia. 1998 Nov 16;12(11):1682-1684.
Goodman, Mark ; Spector, N. ; Rodrigues, G. ; Cassileth, P. A. / Interleukin-2 therapy for advanced chronic myeloid leukemia. In: Leukemia. 1998 ; Vol. 12, No. 11. pp. 1682-1684.
@article{34419018f3264a57bd88e7d52c1ac192,
title = "Interleukin-2 therapy for advanced chronic myeloid leukemia",
abstract = "Chronic myeloid leukemia (CML) is usually treated with either alpha-interferon or hydrea. Median survival is 6 years. Eventually, in most CML patients, the disease evolves to blast phase with clinical and morphologic characteristics of an acute leukemia. This phase is commonly associated with systemic symptoms and the appearance of new cytogenetic abnormalities. Therapy for this phase is of limited value, resulting in a mean survival of 4 months. We describe four consecutive patients seen at our clinic with advanced stage CML (three blast, one accelerated phase) who were treated with interleukin-2 (Proleukin). The mean survival in these patients was 22 months (range 9-35 months) and two are still alive 25 and 35 months after the start of therapy. One patient had a complete cytogenetic response and another a partial response. Toxicity was minimal and no patient had to discontinue therapy because of it.",
keywords = "Blast crisis, Chronic myeloid leukemia, Interleukin-2 therapy",
author = "Mark Goodman and N. Spector and G. Rodrigues and Cassileth, {P. A.}",
year = "1998",
month = "11",
day = "16",
language = "English",
volume = "12",
pages = "1682--1684",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Interleukin-2 therapy for advanced chronic myeloid leukemia

AU - Goodman, Mark

AU - Spector, N.

AU - Rodrigues, G.

AU - Cassileth, P. A.

PY - 1998/11/16

Y1 - 1998/11/16

N2 - Chronic myeloid leukemia (CML) is usually treated with either alpha-interferon or hydrea. Median survival is 6 years. Eventually, in most CML patients, the disease evolves to blast phase with clinical and morphologic characteristics of an acute leukemia. This phase is commonly associated with systemic symptoms and the appearance of new cytogenetic abnormalities. Therapy for this phase is of limited value, resulting in a mean survival of 4 months. We describe four consecutive patients seen at our clinic with advanced stage CML (three blast, one accelerated phase) who were treated with interleukin-2 (Proleukin). The mean survival in these patients was 22 months (range 9-35 months) and two are still alive 25 and 35 months after the start of therapy. One patient had a complete cytogenetic response and another a partial response. Toxicity was minimal and no patient had to discontinue therapy because of it.

AB - Chronic myeloid leukemia (CML) is usually treated with either alpha-interferon or hydrea. Median survival is 6 years. Eventually, in most CML patients, the disease evolves to blast phase with clinical and morphologic characteristics of an acute leukemia. This phase is commonly associated with systemic symptoms and the appearance of new cytogenetic abnormalities. Therapy for this phase is of limited value, resulting in a mean survival of 4 months. We describe four consecutive patients seen at our clinic with advanced stage CML (three blast, one accelerated phase) who were treated with interleukin-2 (Proleukin). The mean survival in these patients was 22 months (range 9-35 months) and two are still alive 25 and 35 months after the start of therapy. One patient had a complete cytogenetic response and another a partial response. Toxicity was minimal and no patient had to discontinue therapy because of it.

KW - Blast crisis

KW - Chronic myeloid leukemia

KW - Interleukin-2 therapy

UR - http://www.scopus.com/inward/record.url?scp=0031726263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031726263&partnerID=8YFLogxK

M3 - Article

C2 - 9823941

AN - SCOPUS:0031726263

VL - 12

SP - 1682

EP - 1684

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 11

ER -